

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYTM

EDITORIAL

Comprehensive Prevention of Occupational Blood Exposures: Lessons From Other Countries

LINDA A. CHIARELLO, RN, MS; DENISE M. CARDO, MD

562

ORIGINAL ARTICLES

Occupational Exposure to Blood: Search for a Relation Between Personality and Behavior

CHRISTIAN RABAUD, MD; AGNÈS ZANEA; JEAN MARIE MUR, MD; MARIE FRANÇOISE BLECH; DIDIER DAZY; THIERRY MAY, MD; FRANCIS GUILLEMIN, MD, PhD

564

Outbreak of Vancomycin-Resistant Enterococci in a Burn Unit

PAMELA S. FALK, MPH; JANICE WINNIKE, BSN; CARLA WOODMANSEE, MT(ASCP); M. DESAI, MD; C. GLEN MAYHALL, MD

575

Comparison of Systematic Versus Selective Screening for Methicillin-Resistant *Staphylococcus aureus* Carriage in a High-Risk Dermatology Ward

EMMANUELLE GIROU, PHARM.D; JOYCE AZAR, MD; PIERRE WOLKENSTEIN, MD; FLORENCE CIZEAU, BSC, CIC; CHRISTIAN BRUN-BUISSON, MD; JEAN-CLAUDE ROUJEAU, MD

583

An Outbreak of *Acinetobacter baumannii*: The Importance of Cross-Transmission

ERIKA M.C. D'AGATA, MD, MPH; VALERIE THAYER, RN; WILLIAM SCHAFFNER, MD

588

Surveillance for Nosocomial and Central Line-Related Infections Among Pediatric Hematology-Oncology Patients

ARNE SIMON, MD; GUDRUN FLEISCHHACK, MD; CAROLA HASAN, MD; UDO BODE, MD; STEFFEN ENGELHART, MD; MICHAEL H. KRAMER, MD, MPH

592

Investigation of an Outbreak of Gram-Negative Bacteremia Among Hematology-Oncology Outpatients

SCOTT R. PENZAK, PHARM.D; PAUL O. GUBBINS, PHARM.D; SHAWNA L. STRATTON, BS; ELIAS J. ANAISSIE, MD

597

CONCISE COMMUNICATIONS

Bloodborne Viral Infections in Patients Attending an Emergency Room in Mexico City: Estimate of Seroconversion Probability in Healthcare Workers After an Occupational Exposure

MIDORI KATO-MAEDA, MD, MS; SAMUEL PONCE-DE-LEÓN, MD, MS; JOSE SIFUENTES-OSORNIO, MD; M. SIGFRIDO RANGEL-FRAUSTO, MD, MS; JUAN CALVA-MERCADO, MD, ME; LOURDES INFANTE-SUAREZ, BS; FERNANDO MORALES VILLAREAL, BS; SERGIO PONCE-DE-LEÓN, MD

600

Long-Term Control of *Legionella* Species in Potable Water After a Nosocomial Legionellosis Outbreak in an Intensive Care Unit

JOSEPH BORAU, MPH; RYAN T. CZAF, BS; KATHLEEN A. STRELLRECHT, PHD; RICHARD A. VENEZIA, PHD

602

Prevalence of Nasal Colonization With Methicillin-Resistant *Staphylococcus aureus* in Selected Patient Populations

MARGARET F. PRICE, PHD; MARIA CARLINI, MD; SUSAN HOUSTON, RN, PHD; LAYNE O. GENTRY, MD

603

Continued inside.

Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.¹
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.²
- Excellent safety profile¹

Single-use tube
(actual size)



The most frequently reported adverse events were headache (9%), rhinitis (6%), respiratory disorder (including upper respiratory tract congestion) (5%), pharyngitis (4%) and taste perversion (3%). Safety in children under 12 years of age has not been established in controlled clinical trials.

Contraindications ... Do not use *Bactroban* Nasal in patients with known hypersensitivity to any of the constituents of the product.

Please see brief summary of prescribing information on adjacent page.

References: 1. *Bactroban*® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

SB SmithKline Beecham
Pharmaceuticals

Bactroban
Nasal mupirocin
calcium
2% ointment for intranasal use

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS

Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS

AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS

General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See **DOSE AND ADMINISTRATION** in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See **CLINICAL PHARMACOLOGY** in complete prescribing information.)

ADVERSE REACTIONS


Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories**, San Antonio, TX 78215
Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101
BRS-BN:L3



INTERNATIONAL CONFERENCE ON INFECTION CONTROL 2000

FACING THE FUTURE

Developing strategies for infection control

13-17 November 2000

Edinburgh International Conference Centre
Scotland, UK

*Study tour including the conference
available for APIC members
Contact APIC for details*

For further information and delegate
booking form, please contact:

**Profile Productions Ltd, 11 The Pavement,
Popes Lane, London, W5 4NG, UK**
Tel: +44 (0) 8832 7300 Fax: +44 (0) 20 8832 7301
E mail: profilep@dial.pipex.com
Full programme at - www.icna.co.uk

Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

MEDICAL MATRIX LLC
<http://www.medmatrix.org>

The largest, peer-reviewed directory to the medical Internet.
Free registration.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- | | |
|--------------------------------------|-------------------------------------|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Manuel Bastanzuri, MD | Havana, Cuba |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Germany |
| Christian Brun-Buisson, MD | Creteil, France |
| Charles Bryan, MD | Columbia, South Carolina |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Robert Gaynes, MD | Atlanta, Georgia |
| Velvl Greene, PhD, MPH | Beer Sheva, Israel |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsiéh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornberry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(856) 848-1000

Executive Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Editorial Assistant
Christine C. Good

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt


Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Tina Panna

Advertising Sales Coordinator
Lori Souder

Classified/Recruitment Sales Manager
Kelly Wark

Classified/Recruitment Sales Representative
Stacey Goldberg



INFECTION CONTROL PRACTITIONER



Visit Eisenhower Medical Center and discover why more and more healthcare professionals are choosing us as their employer of choice - and the Southern California Desert as their permanent home.

Situated on a 100-acre campus located near Palm Springs, we are a dynamic, progressive health care complex comprised of a 261-bed hospital, the Annenberg Center for Health Sciences, the Barbara Sinatra Children's Center, and the Betty Ford Center. A not-for-profit corporation, this multi-faceted institution represents high quality health care for the residents of and visitors to the desert resort communities and provides a full range of educational services for the public and health care professionals.

This full-time position requires a Bachelor's degree; current California RN license; and 3 years' recent experience in an acute clinical setting to include 2 years' in infection control. Computer proficiency is essential; experience with data entry, spreadsheets, and graphics; and ability to collect, analyze, and disseminate data.

In addition to a professional environment and opportunity for advancement, we offer a generous benefit package including relocation reimbursement, a competitive salary, and a beautiful environment in which to live and play. If interested, please call Human Resources to request an employment application at (760) 837-8500 or (800) 854-9261. Eisenhower Medical Center, 39000 Bob Hope Drive, Rancho Mirage, California 92270



EISENHOWER MEDICAL CENTER

Visit our website at www.emc.org

EOE

SHEA

The Society for Healthcare Epidemiology of America

2000 SHEA/CDC Training Course in Hospital Epidemiology

Program

The program will be held October 14-17, 2000 at the Cincinnati Marriott at RiverCenter, Covington, KY. Timothy W. Lane, M.D., Julie Gerberding M.D., and Gina Pugliese, R.N., M.S., will co-chair the program. This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you with the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Jonathan Freeman Scholarships

Seven Jonathan Freeman Scholarships in the amount of \$1,000 each will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$400 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications

for the course is September 1, 2000. The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in late September.

Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	\$525
Fellows in Infectious Disease	\$400

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The Society for Healthcare Epidemiology of America designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (856) 423-7222. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty
U.S. Pharmaceuticals Group

Reducing the hidden costs of nosocomial UTI

Are you even on the map?

The BARDEX® I.C. Foley Catheter can save your hospital up to \$322,000 per year.¹

There are over 900,000 NUTIs each year, costing an average of \$3,800 apiece in non-reimbursable expenses.² These costs often remain hidden because of the complexity of tracking NUTIs.

The silver and hydrogel-coated BARDEX® I.C. Foley Catheter has been proven to reduce the incidence of costly NUTIs by 22-80%. The individual examples shown are just a few of the more than 500 success stories involving hospitals that significantly reduced infection rates – and costs – after converting to the BARDEX® I.C. system.

For more information on the BARDEX® I.C., contact your BARD Representative or call 1-800-526-4455. You can also visit our website at www.bardmedical.com.

Ingelwood, CA
11,381 annual admissions
Annual projected savings
\$187,704
48% reduction in NUTI

Hawthorne, CA
5,000 annual admissions
Annual projected savings
\$119,147
77% reduction in NUTI

Alexandria, LA
9,000 annual admissions
Annual projected savings
\$192,598
62% reduction in NUTI

Hot Springs, Arkansas
12,000 annual admissions
Annual projected savings
\$88,000
80% reduction in NUTI


New Orleans, LA
9,871 annual admissions
Annual projected savings
\$273,600
22% reduction in NUTI

Marietta, OH
6200 annual admissions
Annual projected savings
\$242,000
68% reduction in NUTI

Tampa, FL
40,000 annual admissions
Annual projected savings
\$321,834
36% reduction in NUTI

Baltimore, MD
8650 admissions
Annual projected savings
\$50,000
45% reduction in NUTI

Jersey City, New Jersey
18,000 annual admissions
Annual projected savings
\$148,000
80% reduction in NUTI



References:

1. Data on file, BARD Medical Division, Covington, GA.
2. Hospital Epidemiology and Infection Control, 1996. Nosocomial Urinary Tract Infections, Section III, Chapter 10, p. 140.

BARDEX I.C. is a registered trademark of C.R.BARD, Inc. and its affiliates.

BARD

Bard Medical Division
8195 Industrial Boulevard
Covington, GA 30014
800-526-4455

INFECTION CONTROL AND

Continued from cover

Nosocomial Ringworm in a Neonatal Intensive Care Unit: A Nurse and Her Cat LEWIS M. DRUSIN, MD, MPH; BARBARA G. ROSS, BS, RN; KAREN HELTON RHODES, DVM; ALFRED N. KRAUSS, MD; RACHELLE A. SCOTT, MD	605
INFORMATION MANAGEMENT	
Physician Preferences for Educational Media THERESA L. SMITH, MD; RONDA L. SINKOWITZ-COCHRAN, MPH; WILLIAM R. JARVIS, MD	608
TOPICS IN LONG-TERM CARE	
Tuberculosis in Long-Term-Care Facilities SHOBITA RAJAGOPALAN, MD; THOMAS T. YOSHIKAWA, MD	611
LETTERS TO THE EDITOR	
Prevalence of HIV-1, HBV, and HCV Among Patients Admitted to the Emergency Department of the Hospital de Base of the Federal District, Brazil JULIVAL RIBEIRO, MD; RICARDO BOAVENTURA, MD; RILSON F. MOTTINHO, MD; NEILA F. MOTTINHO, MD; KLEBER N. CAMPOS, MD; RUITER R. SILVA, MSc; GENI N.N.L. CÂMARA, MSc	558
Bacterial Contamination of Hospital Physicians' Stethoscopes UNDINE A.R. THOFERN, PhD	558
A Recent Outbreak of Adenovirus Type 7 Infection in a Chronic Inpatient Facility for the Severely Handicapped TAKAKO UEMURA, MD; TOMOKO KAWASHITAM, MD; YASUSHI OSTUKA, MD; YUJI TANAKA, MD; RYOU KUSUBAE, MD; MASAO YOSHINAGA, MD, PhD	559
Vancomycin-Resistant <i>Enterococcus</i> Stool-Culture-Positive Patients at Charleston Area Medical Center, West Virginia, 1997 to 1999 LYNN W. KITCHEN, MD, MPH	560
EDITOR ACCEPTS NEW POSITION	561
MEDICAL NEWS GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD	617
SHEA NEWS ANDREAS VOSS, MD, PhD	620

To view abstracts of these articles,
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 2000 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$110.00; Two years-\$148.00; Three years-\$181.00; Institutional: One year-\$133.00; Two years-\$183.00; Three years-\$233.00. Fellows: \$55.00 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$150.00 each year; Overseas air mail, \$195.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNDex Top 100.